Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.adro.2020.10.018 http://scihub22266oqcxt.onion/10.1016/j.adro.2020.10.018 33723523!7940781!33723523     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Adv+Radiat+Oncol 2021 ; 6 (2): 100605 Nephropedia Template TP {{tp|p=33723523|t=2021. The Case for Brachytherapy: Why It Deserves a Renaissance |pdf=|usr=}}{{33723523}} gab.com Text The Case for Brachytherapy: Why It Deserves a Renaissance JO: Adv Radiat Oncol http://www.kidney.de/pget.php?&tw=1&pmid=33723523 #FOAvip The recent global events related to the coronavirus disease of 2019 pandemic have significantly changed the medical landscape and led to a shift in oncologic treatment perspectives. There is a renewed focus on preserving treatment outcomes while maintaining medical accessibility and decreasing medical resource utilization. Brachytherapy, which is a vital part of the treatment course of many cancers (particularly prostate and gynecologic cancers), has the ability to deliver hypofractionated radiation and thus shorten treatment time. Studies in the early 2000s demonstrated a decline in brachytherapy usage despite data showing equivalent or even superior treatment outcomes for brachytherapy in disease sites, such as the prostate and cervix. However, newer data suggest that this trend may be reversing. The renewed call for shorter radiation courses based on data showing equivalent outcomes will likely establish hypofractionated radiation as the standard of care across multiple disease sites. With shifting reimbursement, brachytherapy represents the pinnacle in hypofractionated, conformal radiation therapy, and with extensive long-term data in support of the treatment modality brachytherapy is primed for a renaissance. Twit Text FOAVip The Case for Brachytherapy: Why It Deserves a Renaissance ????Adv Radiat Oncol http://www.kidney.de/pget.php?&tw=1&pmid=33723523 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33723523 #FOAvip English Wikipedia <ref>{{Cite pmid|33723523}}</ref> The Case for Brachytherapy: Why It Deserves a Renaissance #MMPMID33723523 Williams VM; Kahn JM; Thaker NG; Beriwal S; Nguyen PL; Arthur D; Petereit D; Dyer BA Adv Radiat Oncol 2021[Mar]; 6 (2): 100605 PMID33723523show ga The recent global events related to the coronavirus disease of 2019 pandemic have significantly changed the medical landscape and led to a shift in oncologic treatment perspectives. There is a renewed focus on preserving treatment outcomes while maintaining medical accessibility and decreasing medical resource utilization. Brachytherapy, which is a vital part of the treatment course of many cancers (particularly prostate and gynecologic cancers), has the ability to deliver hypofractionated radiation and thus shorten treatment time. Studies in the early 2000s demonstrated a decline in brachytherapy usage despite data showing equivalent or even superior treatment outcomes for brachytherapy in disease sites, such as the prostate and cervix. However, newer data suggest that this trend may be reversing. The renewed call for shorter radiation courses based on data showing equivalent outcomes will likely establish hypofractionated radiation as the standard of care across multiple disease sites. With shifting reimbursement, brachytherapy represents the pinnacle in hypofractionated, conformal radiation therapy, and with extensive long-term data in support of the treatment modality brachytherapy is primed for a renaissance. äThe Case for Brachytherapy: Why It Deserves a Renaissance (epmc).pdf DeepDyve Pubget Overpricing